Scleritis (Necrotizing)

1. Comprehensive Introduction & Overview

Necrotizing scleritis represents the most severe and potentially sight-threatening manifestation of scleritis. Unlike non-necrotizing forms (diffuse or nodular), necrotizing scleritis is characterized by profound ocular inflammation that leads to the destruction of the scleral collagen matrix. This condition is frequently associated with systemic autoimmune diseases, most notably rheumatoid arthritis (RA) and granulomatosis with polyangiitis (GPA).

Clinically, the condition is categorized into two primary presentations: necrotizing scleritis with inflammation and necrotizing scleritis without inflammation (scleromalacia perforans). The former is a medical emergency requiring aggressive immunosuppressive intervention to prevent globe perforation, while the latter is often a chronic, indolent process seen in long-standing, seropositive rheumatoid arthritis.

The prevalence of necrotizing scleritis is low, but the morbidity is exceedingly high. Because the sclera is a relatively avascular, dense connective tissue structure, the inflammatory process often triggers localized ischemia, leading to the "melting" of the scleral tissue, exposure of the underlying uvea, and, if left untreated, catastrophic ocular structural failure.

2. Deep-Dive: Pathophysiology and Mechanisms

The pathophysiology of necrotizing scleritis is fundamentally an immune-mediated vasculitis. The sclera relies on a precarious blood supply provided by the episcleral capillary plexus and the deep scleral plexus.

The Mechanism of Tissue Destruction

1. Type III Hypersensitivity: The deposition of immune complexes within the scleral vessel walls triggers the complement cascade, leading to the recruitment of neutrophils and macrophages.
2. Vascular Occlusion: Inflammation leads to fibrinoid necrosis of the scleral vessels. This ischemia is the defining feature; without adequate perfusion, the scleral collagen cannot maintain its structural integrity.
3. Collagenolysis: Activated inflammatory cells release matrix metalloproteinases (MMPs) and reactive oxygen species (ROS). These enzymes degrade the type I collagen bundles that provide the sclera with its tensile strength.
4. Uveal Exposure: As the scleral stroma is resorbed, the underlying dark, vascularized uveal tissue becomes visible, creating the hallmark clinical appearance of a "necrotic patch."

Histopathological Classification

3. Clinical Indications, Presentation, and Staging

Clinical Presentation

Patients typically present with severe, boring, non-radiating ocular pain that often awakens them from sleep. However, in cases of scleromalacia perforans, the patient may be entirely asymptomatic, which is paradoxically more dangerous as the condition progresses unnoticed until the globe is thinned to the point of imminent rupture.

• Pain: The most reliable indicator of active inflammation.
• Photophobia: Due to secondary uveitis.
• Visual Disturbance: Often due to secondary corneal involvement, cataract, or secondary glaucoma.
• Physical Appearance: Bluish-gray hue of the sclera, thinning, and exposure of the uvea (the "choroidal show").

Staging and Grading

Clinical grading is essential for monitoring the efficacy of systemic immunosuppression:

• Grade 1 (Early): Localized hyperemia, early scleral thinning.
• Grade 2 (Intermediate): Multiple patches of necrosis, significant thinning, vascular shutdown.
• Grade 3 (Advanced): Large areas of necrosis, uveal exposure, high risk of staphyloma formation.
• Grade 4 (Perforation): Full-thickness defect, risk of endophthalmitis.

4. Differential Diagnosis

Distinguishing necrotizing scleritis from other ocular surface disorders is critical. Failure to differentiate can lead to inappropriate treatment (e.g., topical corticosteroids which can exacerbate scleral melting).

• Episcleritis: Usually sectoral, mobile vessels, minimal pain, blanches with phenylephrine (scleritis does not).
• Peripheral Ulcerative Keratitis (PUK): Often occurs in conjunction with scleritis; involves the corneal limbus.
• Infectious Scleritis: Usually follows trauma or surgery; requires cultures and targeted antimicrobial therapy.
• Scleral Hyaline Plaques: Benign, age-related; no inflammation, no pain.

5. Diagnostic Workup and Testing

The diagnostic approach for necrotizing scleritis is systemic-focused. Since the ocular condition is often the "sentinel" for a systemic disease, a full rheumatological workup is mandatory.

Essential Diagnostic Tests

1. Complete Blood Count (CBC) & ESR/CRP: Indicators of systemic inflammatory burden.
2. Rheumatoid Factor (RF) & Anti-CCP: Screens for Rheumatoid Arthritis.
3. ANCA (c-ANCA/p-ANCA): Essential for ruling out Granulomatosis with Polyangiitis.
4. Quantiferon-TB Gold: Must be performed before starting high-dose immunosuppressants or biologics.
5. Imaging: B-scan ultrasonography is the gold standard for measuring scleral thickness and detecting posterior scleritis (T-sign).

6. Management: Risks, Side Effects, and Contraindications

Treatment of necrotizing scleritis requires a multi-disciplinary approach (Ophthalmology + Rheumatology).

Therapeutic Pyramid

1. First-line: Systemic corticosteroids (e.g., Prednisone 1mg/kg/day or IV Methylprednisolone pulses).
2. Second-line: Non-biologic DMARDs (Methotrexate, Mycophenolate Mofetil, Cyclophosphamide).
3. Third-line: Biologic agents (Rituximab, Infliximab, Adalimumab).

Risks and Contraindications

• Steroid Risks: Diabetes, osteoporosis, avascular necrosis, psychiatric disturbances.
• DMARD Risks: Bone marrow suppression, hepatotoxicity, infection risk.
• Contraindications: Active systemic infection (e.g., active TB or sepsis) is an absolute contraindication to the initiation of potent immunosuppressive therapy.
• Surgical Contraindication: Avoid scleral grafting in the presence of active, uncontrolled inflammation, as the graft will likely melt.

7. Long-Term Prognosis

The prognosis for necrotizing scleritis is guarded. Without aggressive systemic management, the rate of globe perforation is significant. Even with successful treatment, patients are often left with permanent scleral thinning (staphyloma) and require lifelong monitoring.

• Functional Outcomes: Limited by secondary complications such as cataract formation, secondary glaucoma, and uveitis.
• Systemic Mortality: Patients with necrotizing scleritis associated with systemic vasculitis have higher mortality rates if the systemic disease is not adequately controlled.

8. Massive FAQ Section

1. Is necrotizing scleritis the same as episcleritis?

No. Episcleritis is a benign, self-limiting inflammation of the episclera. Necrotizing scleritis is a destructive, sight-threatening condition involving the deeper scleral layers and is often linked to life-threatening systemic diseases.

2. Can I use eye drops to treat necrotizing scleritis?

Topical corticosteroids are generally ineffective for necrotizing scleritis and can actually speed up the "melting" process. Treatment must be systemic.

3. Why does the sclera turn blue/gray?

The sclera is normally opaque due to the arrangement of collagen fibers. When these fibers are destroyed, the underlying dark, highly vascularized uvea (choroid) shows through the thinned scleral tissue, appearing as a dark blue or gray patch.

4. What is the "T-sign" in B-scan ultrasound?

The T-sign represents fluid in the sub-Tenon's space, which is a classic finding in posterior scleritis but can also be seen in severe necrotizing cases.

5. Why is a rheumatology referral mandatory?

Over 50% of patients with necrotizing scleritis have an undiagnosed or poorly controlled systemic autoimmune disease. Treating the eye alone is insufficient and dangerous.

6. Can this condition lead to blindness?

Yes. If the necrosis causes the globe to perforate, the risk of endophthalmitis and subsequent phthisis bulbi (shrunken, non-functioning eye) is extremely high.

7. What is the role of surgery in necrotizing scleritis?

Surgery (such as a scleral patch graft) is reserved for structural stabilization once the systemic inflammation has been brought under control. Operating during active inflammation is almost always unsuccessful.

8. Is pain a reliable indicator of improvement?

Yes. In inflammatory necrotizing scleritis, the resolution of pain is one of the earliest and most reliable signs that the immunosuppressive therapy is working.

9. Why is Rituximab used for this condition?

Rituximab is a monoclonal antibody that targets CD20+ B-cells. It has shown excellent efficacy in treating refractory necrotizing scleritis, particularly in cases associated with ANCA-associated vasculitis.

10. Can necrotizing scleritis recur?

Yes. Because it is almost always associated with chronic systemic autoimmune conditions, patients remain at risk for recurrence throughout their lives, necessitating long-term surveillance.

9. Summary Table: Clinical Management

Disclaimer: This guide is intended for educational purposes for healthcare professionals. Clinical management of necrotizing scleritis must be individualized based on the patient’s systemic health, comorbid conditions, and response to therapy. Always consult with a rheumatologist when managing these patients.